Report cover image

COVID-19 Impact on Global Recombinant Vaccines Market By Patient Type (Pediatric and Adult Patients); By Technology (Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines and Toxoid Vaccines) and Region –Anal

Publisher Fatpos Global
Published May 01, 2022
SKU # FAGL17317416

Description

COVID-19 Impact on Global Recombinant Vaccines Market By Patient Type (Pediatric and Adult Patients); By Technology (Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines and Toxoid Vaccines) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030

COVID-19 Impact on Global Recombinant Vaccines Market By Patient Type (Pediatric and Adult Patients); By Technology (Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines and Toxoid Vaccines) and Region –Analysis of Market Size, Share and Trends for 2014 – 2019 and Forecasts to 2030

*Please Note: The report will be delivered in 4-5 business days upon order confirmation*

Table of Contents

1. Executive Summary
2. Recombinant Vaccines Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Market Dynamics
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends
6. Correlation & Regression Analysis
6.1. Correlation Matrix
6.2. Regression Matrix
7. Recent Development, Policies & Regulatory Landscape
8. Risk Analysis
8.1. Demand Risk Analysis
8.2. Supply Risk Analysis
9. Recombinant Vaccines Market Analysis
9.1. Porters Five Forces
9.1.1. Threat of New Entrants
9.1.2. Bargaining Power of Suppliers
9.1.3. Threat of Substitutes
9.1.4. Rivalry
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. Recombinant Vaccines Market
10.1. Market Size & forecast, 2019A-2030F
10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11. Recombinant Vaccines Market: Market Segmentation
11.1. By Regions
11.1.1. North America:(U.S. and Canada)
11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12. Recombinant Vaccines Market: Market Segmentation
12.1. By technology: Market Share (2020-2030F)
12.1.1. conjugate vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.2. inactivated and subunit vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.3. live attenuated vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.4. recombinant vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.5. toxoid vaccines, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2. By patient type : Market Share (2020-2030F)
12.2.1. pediatric, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.2. adult patients, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
13. Company Profile
13.1. Johnson and Johnson
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Abiomed
13.3. Emergent Bio Solutions, Inc.
13.4. GlaxoSmithKline
13.5. Sanofi Pasteur SA
13.6. Serum Institute of India Pvt. Ltd
13.7. Mitsubishi Tanabe Pharma Corporation
13.8. Daiichi Sankyo
13.9. Pfizer, Inc.
13.10. Other prominent players
Consultant Recommendation
**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us